I have more than 20 years of experience in biomedical research with interdisciplinary teams including academics and clinicians, in the field of cancer immunology and immunotherapy, inflammatory and infectious diseases with a special focus on NK cell and T-lymphocyte-specific cellular immunity. I lead the reference group Immunotherapy, inflammation and cancer at the IISA and lead a group in CIBERINFECT developing lines related to the study of immunity and development of cellular immunotherapy in infectious diseases. I have participated in several national and EU projects (15 competitive projects in 11 of which I have been IP with a total funding of 4.7 million Euros and 7 R&D contracts in all as IP with a total funding of 2.750,000 Euros) . Among other achievements, my laboratory was the first to describe the role of gzms (T and NK lymphocyte proteases) in cancer, apoptosis induced by Tc-derived gzms, or the role of gzmA in arthritis, sepsis and inflammatory colorectal cancer. The impact of our results in the field is backed by the recent invitation to review this area in Nature Reviews Rheumatology (2024). We are currently evaluating the role of gzmA-mediated inflammation in several observational studies, including sepsis, influenza or COVID19, designed with clinical investigatorsm asupporting the translational relevance or our research. In addition, I coordinate the WP related with CART cell development within the prestigious EU advanced ERC ICOMICS and ERC proof of concept VASTO project aimed at studying the mechanical role of the tumor microenvironment in the efficacy of CARTs against solid tumors, led by JM Garcia Aznar